Here are the 8-K filings from Bioscience Health Innov (BHIC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow BHIC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHIC filings page.
Bioscience Health Innovations, Inc. reported a change to its Board of Directors. On April 1, 2026, director Justin Earl resigned, and the company stated his resignation was not due to any disagreement over operations, policies, or practices.
On the same day, the Board appointed Daniel Schmidt, the company’s long-time Chief Technology Officer, to fill the vacant board seat, effective immediately. Schmidt brings 26 years of experience developing and commercializing therapeutic medical devices and treatments aimed at improving quality of life.
BioScience Health Innovations, Inc. effected a reverse stock split, consolidating every 4 shares of common stock into 1 share, effective September 10, 2025. The Board approved the action under Nevada law, and a majority of shares entitled to vote approved it by written consent.
The company states the reverse split does not affect stockholder rights, and no other amendments were made to the certificate of incorporation. A certificate of amendment was filed with the Nevada Secretary of State.